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Background: Oral cancer develops through multi-stages: from normal to mild (low grade) dysplasia (LGD),
moderate dysplasia, and severe (high grade) dysplasia (HGD), to carcinoma in situ (CIS) and finally invasive oral
squamous cell carcinomas (OSCC). Clinical and histological assessments are not reliable in predicting which
precursor lesions will progress. The aim of this study was to assess the potential of a noninvasive approach to
assess progress risk of oral precancerous lesions.
Methods: We first used microRNA microarray to profile progressing LGD oral premaligant lesions (OPLs) from non-
progressing LGD OPLs in order to explore the possible microRNAs deregulated in low grade OPLs which later
progressed to HGD or OSCC. We then used RT-qPCR to detect miRNA targets from the microarray results in saliva
samples of these patients.
Results: We identified a specific miRNA signature that is aberrantly expressed in progressing oral LGD leukoplakias.
Similar expression patterns were detected in saliva samples from these patients.
Conclusions: These results show promise for using saliva miRNA signature for monitoring of cancer precursor
lesions and early detection of disease progression.
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Oral squamous cell carcinomas (OSCCs) are among the
most common types of head and neck cancers and are a
major cause of significant morbidity. It was reported that
16–62% of OSCCs develop from premalignant lesions
[1], which often presents clinically as white or red muco-
sal patches called leukoplakia and erythroplakia. Early
detection of cancer development from oral premalignant
lesions (OPLs) plays a crucial role in successful therapy.
Currently risk of progression in oral leukoplakia is typic-
ally determined based on clinical assessment and histo-
pathological evaluation of biopsied material. High grade
dysplasia (HGD) and carcinoma in situ (CIS) are consid-
ered to have a high risk for progression to invasive
disease. In contrast, most of the low grade dysplasias
(LGDs) remain unchanged for years or even resolve over* Correspondence: julieyy@163.com
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reproduction in any medium, provided the ortime [2]. But a small proportion of these LGDs may pro-
gress to carcinomas [3]. Clinical and histological charac-
teristics cannot be used to separate “progressing” and
“non-progressing” LGDs [4]. There is therefore an
urgent need to find predictive biomarkers that can aid in
defining progression likelihood of LGDs, which repre-
sent the majority of diagnosed OPLs.
miRNAs are an abundant class of small 18–25 nucleo-
tides long single-stranded non-coding RNA. These non-
coding RNAs participate in a variety of biologic processes
including development, differentiation, apoptosis and
proliferation through regulating its target genes [5-8].
Notably, a single miRNA is capable of regulating the
translation of a multitude of genes [9]. And they are
remarkably stable both in saliva samples and in tissue
samples [10,11], which offers a great advantage over
other classes of biomarkers and also an extremely im-
portant characteristic in clinical settings. The control of
gene expression by miRNAs is a process seen in virtu-
ally all cancer cells. Recently, a bundle of studies have
showed that miRNAs might behave as cancer ‘drivers’d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ute to the progression from premalignant lesion to
cancer [12-14]. Only a small number of studies have
investigated miRNA expression profiles in the malig-
nant transformation of OPLs, and there is no report yet
about investigating salivary miRNAs changes in this
type of patients. Cervigne et al. examined miRNA
expression changes in tissue samples during progres-
sion of oral malignancy [15]. Wiklund et al. demon-
strates that Certain OSCC specific miRNA are both
present and detectable in oral fluids [16]. However
salivary miRNA changes involved in the transformation
of oral leukoplakias remain poorly understood.
With an aim to investigate the potential of using salivary
microRNA biomarkers to assess the risk of malignant trans-
formation, our study includes the analysis of progressing
and non-progressing LGD leukoplakias with similar
histopathological diagnosis but different clinical out-
comes. We first used microRNA microarray to profile
progressing LGDs from non-progressing LGDs. We
identified a specific miRNA signature that is aberrantly
expressed in oral LGD leukoplakias which later
progressed to HGDs or CISs and even OSCCs. Similar
miRNA deregulation patterns were detected in saliva
samples of these patients. These results indicated the
feasibility of a noninvasive assay for risk assessment of
oral precancerous lesions based on salivary miRNA
signatures.
Methods
Patients and samples collection
From 2006 to 2012, 45 eligible patients treated in the
department of Oral & Maxillofacial-Head & Neck
Oncology, Ninth People’s Hospital, Shanghai Jiao Tong
University (Shanghai, China) were enrolled in the
present study. The patients had been diagnosed with
LGD leukoplakias and were given 13-cis-retinoic acid
(13cRA) treatment and close follow-ups before any
event (defined as the diagnosis of HGD or CIS or
OSCC). The diagnosis of leukoplakias, OSCC, and LGD
were made according to World Health Organization
criteria [17]. A total of 45 frozen samples were col-
lected at baseline after enrollment. Among these 45
LGD leukoplakias patients, 10 patients progressed to
carcinoma in situ or OSCC after an average time of
30.1 months. 2 were excluded because of poor RNA
quality. Among the 35 patients who did not develop
OSCC, 5 were excluded because of poor RNA quality,
and another 12 were excluded because of new lesion
occurrence. As these progressing LGD samples are very
rare and difficult to obtain, we included all the 8
samples from patients who developed oral cancer (N = 8)
for gene expression profiling. 7 patients who remained at
a LGD stage within 3–5 years of follow-up were selected,in order to identify the differences in miRNA expression
between these precancerous lesions with different clinical
outcomes. Informed consent was obtained from all
patients. The project was approved by the Scientific and
Ethics Committee of Shanghai Jiao Tong University. Patient
information and representative histological pictures is
shown in Table 1 and Figure 1, respectively.
Saliva samples were collected from these patients when-
ever tissue biopsies were collected. But only samples col-
lected at first visit were used for analysis in order to
investigate miRNA expression differences in these prema-
lignant lesions at LGD stage. Saliva samples from 7
healthy volunteers were also collected to determine base-
line miRNA expression in oral saliva from normal control.
Briefly, immediately after mouthwash, ~2 ml saliva was
collected. Upon collection, saliva samples were mixed with
5 ml RNA Protect Saliva reagent (Qiagen, Copenhagen),
kept at room temperature for 24 hours, and then stored
at −20°C until RNA or protein isolation.
RNA extraction, cDNA synthesis and miRNA expression
profiling for tissue samples
The TaqManW low density array (TLDA) qRT-PCR
system (Applied Biosystems, Foster City CA) were used
for global miR expression analysis. Briefly, total RNA
was extracted using TRIzol reagent (Invitrogen).The
qualities of RNA extracts were found to be good. Total
RNA was converted into specific cDNA derived from
mature miRs and quantified using Multiplex RT and
TaqMan Low Density Array (TLDA) Human MicroRNA
Panel v3.0 and 7900 real-time RT PCR System (Applied
Biosystems). A total of 800 ng RNAs were used for each
array. The two-card set of TaqManW Array MicroRNA
Cards (Cards A and B) contained 754 lyophilized human
TaqMan miR sequences. And each card contains four
control assays—three carefully selected candidate endogen-
ous control assays and one negative control assay.
RNA extraction, cDNA synthesis and miRNA quantification
for saliva samples
Real-time qPCR analysis was performed on saliva sam-
ples from these patients and 7 healthy volunteers using
the TaqMan MicroRNA Assay. miRNA expression ana-
lysis was performed for 8 selected deregulated miRNAs
(miR-10b, miR-145, miR-99b, miR-708, miR-181c, miR-
30e, miR-660 and miR-197) with greatest fold changes in
progressing LGD leukoplakias compared with non-
progressing LGD leukoplakias.
Total RNA was extracted from saliva samples using the
RNeasy Micro Kit (Qiagen, Hilden, Germany) according to
the manufacturers’ protocols. In brief, the saliva sample is
first centrifuged, and Buffer RLT is then added to the
resulting pellet. After addition of ethanol, the sample is ap-
plied to an RNeasy MinElute spin column, where RNA
Table 1 Sample set of oral LGD leukoplakias
Histopathological Tobacco Duration of
Patients Lesion site Diagnosis Age Sex Exposure follow-up(mo)
1 Left lateral tongue Mild to moderate dysplasia 45 female former smoker 40
2 Right lateral palatine Mild to moderate dysplasia 67 male current smoker 36
3 Right lateral palatine Mild to moderate dysplasia 55 female never smoked 39
4 right lateral tongue Mild to moderate dysplasia 54 female never smoked 36
5 right cheek mucosa Mild to moderate dysplasia 64 male current smoker 43
6 right cheek mocusa Mild to moderate dysplasia 57 male current smoker 46
7 left cheek mucosa Mild dysplasia 61 male current smoker 39
8 left lateral tongue Severe dysplasia SCC micro-foci 71 male current smoker 29
9 lower lip Severe dysplasia, SCC micro-foci 60 female never smoked 28
10 left cheek Severe dysplasia SCC micro-foci 52 female former smoker 34
11 palate Severe dysplasia 55 female never smoked 35
12 left cheek Severe dysplasia 66 male former smoker 30
13 right lateral tongue carcinoma in situ 61 female never smoked 29
14 right lateral tongue carcinoma in situ 71 male current smoke 30
15 left cheek moderate to severe dysplasia SCC micro-foci 59 male current smoker 26
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omic DNA are removed by DNase digestion, and contami-
nants are washed away in several wash steps. Highly pure
RNA is then eluted using RNase-free water in a volume of
just 14 μl. The purity of isolated RNA was determined
by OD260/280 using a Nanodrop ND-1000 (Thermo
Scientific, Worcester, MA). Each RNA sample wasFigure 1 Representative histological pictures of OPLs and OSCCs. (A)
with moderate epithelia dysplasia; (C) oral leukoplakia with high grade epit
cell carcinoma.polyadenylated and reversely transcribed to cDNA using the
TaqManW MicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA Single-stranded cDNA was
synthesized from 10 ng of total RNA(normalization by
amount) or from 1 μl of the RNA volume (normalization
by volume) using specific miRNA primers (TaqMan
MicroRNA Assay, PN 4427975, Applied Biosystems).oral leukoplakia with low grade epithelia dysplasia; (B) oral leukoplakia
helia dysplasia; (D) cancerated leukoplakia; (E) invasive oral squamous
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were normalized against RNU6; pooled saliva samples from
healthy volunteers were used as the reference for analysis.
Statistical analyses
Samples were grouped as normal, non-progressive LGD
leukoplakia and progressive LGD leukoplakia. Data were
quantified and analyzed using Sequence Detection System
(version 2.3) (Applied Biosystems). The expression level of
each miRNA was quantified by its normalized threshold
cycle number ΔCt, where ΔCt = [Ct (miRNA)]-[Ct (U48)],
and the relative expression level was calculated as 2-(ΔCt)
which is commonly used in genom-wide profiling studies
of miRNAs. In order to select differentially expressed
miRNAs for further classification, the random variance
t-test (RVM t-test) was used to compare the control
and experiment, as the RVM t-test can raise degrees of
freedom effectively in the cases of small samples. The
multiple testing was corrected using the Benjamini–
Hochberg false discovery rate (FDR) method. Having aTable 2 miRNAs differentially expressed between progressing
Mean intensity in Mean intensity in

























miR-9 21.1533 17.9955differential fold change > ±2 at raw P value < 0.05 were
considered as significant candidates.
Expression levels of selected miRNAs in saliva samples
of these patients were calculated with U6 as normalization
factor. Comparison of raw U6 values between different
groups showed no significant difference (p = 0.09, Mann–
Whitney U test). Raw data were normalized by subtracting
the U6 CT values from the marker CT values. Statistical
comparisons were made with the use of student’s t-tests
for two groups. Data analyses were performed using SPSS
for Windows version 16.0 (SPSS Inc., USA). Tests were
two-sided and p ≤ 0.05 was considered statistically
significant.
Results
miRNA expression profiling in different types of LGD
lesions
In order to evaluate miRNA deregulations of progressive
oral premalignant lesions, we used a systematic miRNA
expression profiling analysis of 754 mammalian miRNAs-LGD leukoplakias and non-progressing-LGD leukoplakias
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http://www.biomedcentral.com/1471-2407/13/129on 8 progressing LGD leukoplakias and 7 non-progressing
LGD leukoplakias. A filter procedure reduced the number
of miRNAs to a total of 617 hsa-miRNAs, eliminating
genes with low expression variation across the experiments
(SD < 0.3). We performed a differential expression analysisFigure 2 Differentially expressed miRNAs between progressive LGD le
showing the differentially expressed mirRNAs between progressing LGDs a
red, repressed miRNAs are colour-coded green.to detect significant differences in miRNA expression be-
tween different types of LGD leukoplakias.
We identified 25 miRNAs differentially expressed be-
tween progressive and non-progressive LGD leukoplakias.
Compared to non-progressive LGD leukoplakias, 13ukoplakias and non-progressive LGD leukoplakias. Heat map
nd non-progressing LGDs. Over-expressed miRNAs are colour-coded
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up-regulated in progressive LGD leukoplakias. According
to previous studies on oral squamous cell carcinomas,
most of these deregulated miRNAs in progressive LGD
leukoplakias were changed with same changing patterns
as that in OSCC, such as down-regulation of miR-99,
miR-let-7, miR-145 and up-regulation of miR-708, miR-
10b, miR-26a and miR-30e. Interestingly, in our study
both miR-181c and miR-181b were found to be under-
expressed in progressing LGD leukoplakias, which was
contrary to the result of a previous study on miRNA ex-
pression changes during progression of oral premalignancy.
The miRNAs that were differentially expressed are listed in
Table 2 and Figure 2.
Detection of deregulated miRNA expressions in saliva
To explore the possibility of using salivary microRNA
markers to distinguish OPL patients with different
malignant transform potential, we tested the expression
of 8 miRNAs (miR-10b, miR-145, miR-99b, miR-708,
miR-181c, miR-30e, miR-660 and miR-197) in saliva
samples from these patients using qRT-PCR. According
to the TLDA findings, miR-10b, miR-660, miR-708 and
miR-30e demonstrated significant over-expression inFigure 3 Detection of miRNA targets by qRT-PCR in saliva samples fro
leukoplakias as well as healthy volunteers. Differences were estimatedprogressive LGD leukoplakias; miR-145, miR-99b, miR-
181c and miR-197 were under-expressed in this group of
leukoplakias.
Expressions of miR-10b, miR-145, miR-99b, miR-708
and miR-181c were significantly different in saliva of
progressive LGD leukoplakia patients, compared to that
of non-progressive LGD leukoplakia patients (Figure 3).
Trend (P < 0.10) were observed for miR-197 and miR-
30e, the p-values were 0.057 and 0.089 respectively.
Expression of miR-660 was under-expressed in non-
progressing LGD leukoplakias (p = 0.038) but over-
expression of this miRNA in progressing leukoplakias
did not reach statistical significance (P = 0.098), which
was inconsistent with our initial TLDA findings of this
gene in progressing leukoplakias.
Discussion
Patients with oral premalignant changes consist of a
diverse population and should be treated differently
depending on their molecular genotype. There is an
urgent need to identify which leukoplakia will progress
and which will not. The search for genetic biomarkers of
tumor progression is one of the potential approaches.
miRNA expression profiling has been able to identifym patients with progressing and non-progressing LGD
by t-test and p values are shown for each comparison.
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sion. And abnormal changes in miRNA expression have
been identified in patients’ bodily fluids, such as blood,
urine, and saliva [18,19]. In order to explore the possibil-
ity of salivary miRNA analysis as a method aiding in risk
assessment of OPL, we examined miRNA expression in
paired tissue and saliva samples from patients with
histopathologically similar leukoplakias but different
clinical outcomes. We successfully detected in OPL
patients’ saliva samples those miRNAs which were differ-
entially expressed in OPL tissue samples. We found that
saliva contains these deregulated miRNAs in much lower
amounts, but they are present in this fluid and the chan-
ging patterns are similar with that in tissue samples.
In the present study we observed up-regulations of
miR-708, miR-10b, miR-19a, miR-30e, miR-26a, miR-660
and down-regulations of miR-99, miR-15a, miR-197,
miR-145 and miR-150. The same changing patterns have
been reported in other cancers, including oral squamous
cell carcinomas. However, we noticed miR-181c and miR-
181b were found to be under-expressed in progressing
LGD leukoplakias and over-expressed in non-progressive
LGD leukoplakias, which was contrary to the result of a
previous study. The miR-181 family members were identi-
fied as either tumor suppressors or oncogenes in various
cancers depending on tissue types [20-22]. Cervigne N.K.
et al. reported that they found a gradual increase in ex-
pression of miR-181b in tissue samples during oral car-
cinogenesis, suggesting miR-181b plays as an oncogenic
gene in oral cancer [15]. Our results were contrary to this
but in concordance with results of some recent studies.
For example, decreased serum miR-181a was found in
breast cancer patients, especially early stage breast
cancer patients (ductal carcinoma in situ, TNM I and II)
[23]. Visone R. et al. found that during the course of the
disease the expression of miR-181b was decreased in
samples of patients with a progressive but not in sam-
ples of patients with a stable disease. It seems that miR-
181 family members may act as tumor suppressors in
tumor initiation and decreased expression of these genes
may contribute to progression from precursor lesions to
tumors. Further studies needed to clarify this point.
We also noticed that a group of miRNAs are over-
expressed in non-progressing LGD leukoplakias com-
pared with progressing LGD leukoplakias. Among them
are miR-197, miR-let-7, miR-99a/b, miR-126 and miR-145.
These over-expressed miRNAs are known for their tumor
suppressive roles in cancers. The marked up-regulation of
these miRNAs in this group of patients implies that these
stable LGD lesions may possess some mechanisms of pro-
tection from malignant transformation.
Several important conclusions can be made from the
encouraging results of our study. Firstly, some miRNAs
are differentially expressed in LGD leukoplakias withdifferent progression potentials. Secondly, these differen-
tially expressed miRNAs can be detected in both tissue
samples and saliva samples as early as at LGD stage.
Thirdly, Salivary miRNA analysis is a promising non-
invasive assay for early detection and monitoring of oral
premalignancies. But it should also be noted that our re-
sults were drawn from a small number of patients, as
these progressing LGD leukoplakias are rare and very dif-
ficult to obtain. The different microRNA patterns are not
intended to draw any disease specific conclusions and
shown only as a proof of concept. However, when we
compared the miRNA expression profiles of these LGD
leukoplakias with different clinical outcomes, we did dem-
onstrate a clear segregation between them and the similar
expressions were detected in saliva samples of these pa-
tients. These preliminary results are suggestive to further
develop this approach and the actual clinical value of this
approach needs to be approved in larger cohort studies in
high-risk groups.Conclusion
Right now biopsy should still remain the gold standard
in diagnosing oral precancer and oral cancer. However,
detection of deregulated miRNA biomarkers in saliva
samples is a promising noninvasive assay for risk assess-
ment of LGD oral precancerous lesions, which may add
value to the histologic diagnosis.
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